 |
|
Bare-metal stents are better for some heart patients
May 14, 2007(PHILADELPHIA) -- While drug-eluting stents are effective in keeping open diseased heart arteries, they should not be used for patients who need to have non-cardiac surgery a short time after an interventional heart procedure. A presentation at the Society for Cardiovascular Angiography and Interventions in Orlando by cardiologists at Jefferson Medical College indicates that for these patients, bare metal stents provide a safer choice.
"The issue here," says Michael Savage, M.D., Catheterization Laboratory Director at Thomas Jefferson University Hospital in Philadelphia, "is that studies have demonstrated that those patients who receive drug-eluting stents may develop life-threatening cardiac complications if they undergo subsequent, non-cardiac surgery."
This prescription for the potentially deadly problem begins when a person, often a senior citizen, learns that she or he must have elective surgery. The surgery can be for a minor to a major problem--from vacular surgery to fix blood flow problems, to broken hips or bones, neurological or urological issues and more.
Often, severe coronary artery disease is discovered during the pre-surgical testing. If severe, it presents a more-immediate problem and therefore, must be treated before the patient undergoes the elective surgery.
Prior studies have shown that patients may suffer fatal heart attacks due to clotting inside of the stents when surgery is performed within a few weeks after stent placement. In the case of drug-eluting stents, clotting of the stent may occur even months or years after their heart procedure, particularly when their blood thinning medicine (usually aspirin and Plavix) are stopped before the surgery.
To avoid the potentially deadly scenario, the Jefferson Medical College researchers developed a clinical protocol to enable patients to have both procedures successfully with little risk. Led by Agostino Ingraldi, M.D., a fellow in cardiovascular diseases, they developed the following four-part strategy:
* Avoidance of drug-eluting stents in favor of bare metal stents during the interventional heart procedure.
* A four-week course of the blood thinner clopidogrel (Plavix) after an interventional heart procedure.
* Deferral of the second, non-cardiac surgery for five to 12 weeks after the interventional procedure.
* Discontinuation of clopidogrel (Plavix) at least five days prior to the non-cardiac surgery.
The researchers studied a total of 60 patients (33 men and 27 women) who averaged 68 years old and who were treated with the strategy. Twenty seven percent suffered from diabetes which can complicate surgery.
The results show the coronary interventional procedure was successful in all patients where a total of 82 heart lesions were treated with bare-metal stents. The second, non-cardiac, surgery was performed an average of 47 days later. All were performed under general anesthesia and were successful. There were no deaths or clotting leading to problems. Also, clotting of the stents--a major problem seen with drug-eluting stents in this setting--were not seen in any patient.
"This research provides a safe treatment strategy for interventional cardiologists and their patients who will be undergoing further surgery," adds Dr. Savage, who is also associate professor of Medicine, Jefferson Medical College of Thomas Jefferson University. "Drug-eluting stents have proven benefits but may not be the best solution for every patient."
Thomas Jefferson University
Often, severe coronary artery disease is discovered during the pre-surgical testing. If severe, it presents a more-immediate problem and therefore, must be treated before the patient undergoes the elective surgery.
Prior studies have shown that patients may suffer fatal heart attacks due to clotting inside of the stents when surgery is performed within a few weeks after stent placement. In the case of drug-eluting stents, clotting of the stent may occur even months or years after their heart procedure, particularly when their blood thinning medicine (usually aspirin and Plavix) are stopped before the surgery.
To avoid the potentially deadly scenario, the Jefferson Medical College researchers developed a clinical protocol to enable patients to have both procedures successfully with little risk. Led by Agostino Ingraldi, M.D., a fellow in cardiovascular diseases, they developed the following four-part strategy:
* Avoidance of drug-eluting stents in favor of bare metal stents during the interventional heart procedure.
* A four-week course of the blood thinner clopidogrel (Plavix) after an interventional heart procedure.
* Deferral of the second, non-cardiac surgery for five to 12 weeks after the interventional procedure.
* Discontinuation of clopidogrel (Plavix) at least five days prior to the non-cardiac surgery.
The researchers studied a total of 60 patients (33 men and 27 women) who averaged 68 years old and who were treated with the strategy. Twenty seven percent suffered from diabetes which can complicate surgery.
The results show the coronary interventional procedure was successful in all patients where a total of 82 heart lesions were treated with bare-metal stents. The second, non-cardiac, surgery was performed an average of 47 days later. All were performed under general anesthesia and were successful. There were no deaths or clotting leading to problems. Also, clotting of the stents--a major problem seen with drug-eluting stents in this setting--were not seen in any patient.
"This research provides a safe treatment strategy for interventional cardiologists and their patients who will be undergoing further surgery," adds Dr. Savage, who is also associate professor of Medicine, Jefferson Medical College of Thomas Jefferson University. "Drug-eluting stents have proven benefits but may not be the best solution for every patient."
Thomas Jefferson University
Stents Current Events and Stents News RSSYour Own Stem Cells Can Treat Heart Disease
The largest national stem cell study for heart disease showed the first evidence that transplanting a potent form of adult stem cells into the heart muscle of subjects with severe angina results in less pain and an improved ability to walk. The transplant subjects also experienced fewer deaths than those who didn't receive stem cells.
Vitamin B niacin offers no extra benefit to statin therapy in seniors already diagnosed with CAD
The routine prescription of extended-release niacin, a B vitamin (1,500 milligrams daily), in combination with traditional cholesterol-lowering therapy offers no extra benefit in correcting arterial narrowing and diminishing plaque buildup in seniors who already have coronary artery disease, a new vascular imaging study from Johns Hopkins experts shows.
Higher carotid arterial stenting rates associated with poorer clinical outcomes
Among eligible Medicare beneficiaries, increased use of carotid arterial stenting (CAS) procedures to treat carotid stenosis-the narrowing of the carotid artery-is associated with higher rates of mortality and adverse clinical outcomes, including heart attack and stroke, according to researchers from the University of Pennsylvania School of Medicine.
Drug-eluting stents better than bare-metal stents for heart attack patients
Late-breaking data from the landmark HORIZONS-AMI clinical trial, presented at the 21st annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, demonstrated that after two years, in heart attack patients, the use of a drug-eluting stent (paclitaxel) was safer and more effective than a bare-metal stent; and that the administration of the anticoagulant medication bivalirudin enhanced safety and efficacy compared to the use of heparin + GPIIb/IIIa inhibitors.
SPIRIT IV trial shows everolimus stent sets new standard for event-free survival
Late-breaking data from SPIRIT IV, a large-scale multi-center study of nearly 4,000 patients in the U.S., shows that an everolimus-eluting stent demonstrated enhanced safety and efficacy in the treatment of de novo native coronary artery lesions when compared to a paclitaxel-eluting stent, and showed that "low late loss" may be achieved with drug-eluting stents without sacrificing safety.
Drug-eluting stents safe, effective for treatment of chronic total occlusions
A multicenter study in Asia found drug-eluting stents effective with a low rate of acute complications in patients with chronic total occlusions (CTOs) undergoing PCI. Results of the study will be presented at the 21st annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation (CRF).
Researchers find drug-eluting stents safe, effective for PCI in diabetics
Results of a multicenter study in Asia, demonstrating that drug-eluting stents are effective with a low rate of complications in diabetic patients, will be presented at the 21st annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation (CRF).
New type of sirolimus-eluting stent demonstrates superior results
A new type of sirolimus-eluting stent (SES) successfully showed significantly greater neointimal suppression than the paclitaxel-eluting stent (PES) with greater vessel wall integrity surrounding the stent, confirming the finding of superiority of the SES over the PES stent for the trial's primary endpoint of in-stent late loss.
Laser processes promise better artificial joints, arterial stents
Researchers are developing technologies that use lasers to create arterial stents and longer-lasting medical implants that could be manufactured 10 times faster and also less expensively than is now possible.
Stent for life initiative
Primary angioplasty (with stent implantation) is the most effective therapy for acute myocardial infarction (AMI), but it is not available to many patients, even though most European countries have sufficient resources (ie, catheterisation laboratories) for its wider use.
More Stents Current Events and Stents News Articles
 |
Handbook of Coronary Stents by Patrick W. Serruys (Editor), Benno J. Rensing (Editor) Erasmus Univ., Rotterdam, The Netherlands. Handbook provides details of all the specifications of the currently available stents and illustrates each chapter with case studies and photographs of the stents themselves. Previous edition: c2000. |
 |
Acmi Corporation Stent-1 .028x100cm Ptfe Coated by ACMI Corporation ACMI CORPORATION STENT-1 .028X100CM PTFE COATED : ACMI CORPORATION STENT-1 .028X100CM PTFE COATED |
 |
Drug-eluting Stents: Are they Safe? Drug-eluting stents are metal mesh tubes coated with medication that keep arteries from re-blocking after angioplasty. These devices have been the solution for millions of people around the world. However, recent studies have raised concerns about associated risks. Join Dr. Yeung and colleagues as they discuss the safety of these popular devices This product is manufactured on demand using DVD-R recordable media. Amazon.com's standard return policy will apply. |
|
KR3W The Dixon Stent Jacket,Jackets for Men, Medium,Teal by KR3W KR3W The Dixon Stent Jacket,Jackets for Men: Model is wearing a size MEDIUM The Dixon Stent Jacket has a 100% cotton shell and 100% polyester lining and filling and features a supersoft cotton knit with a lumberjack knit pattern a button-down front and two buttoned chest pockets. By KR3W | |
 |
Stents and Sensibility Starring: Dr. James Ferguson Directed By: John Siceloff Also With: John Siceloff (Producer), David Brancaccio (Writer) |
 |
STENT 'S Beer and Ale Cascading Pub Wall Clock by ZuWEE 9" Black Plastic Wall Clock. Brand new in box. Precision quartz movement operates on one AA battery (not included). This is not a lighted clock. |
![Ooh La La [4 track Aussie maxi single]](http://ecx.images-amazon.com/images/I/41lSQrycZtL._SL160_.jpg) |
Ooh La La [4 track Aussie maxi single] Goldfrapp (Performer), Mark "Spike" Stent (Performer), Benny Benassi (Performer), Phones (Performer), Jochen Schmalbach (Performer), Tiefschwarz (Performer), Charlie Jones (Performer), Adrian Utley (Performer), Nick Batt (Performer) Tracklisting: 1 Ooh La La (Radio Version) (2:56) Mixed By - Mark "Spike" Stent* 2 Ooh La La (Benny Benassi Remix - Extended) (6:50) Remix - Alle Benassi , Benny Benassi 3 Ooh La La (Phones Re-Edit) (6:29) Remix - Phones 4 Ooh La La (Tiefschwarz Dub) (6:36) Remix - Jochen Schmalbach , Tiefschwarz |
 |
When The Blues Get The Cup Harvey Andrews with Guest Narrator Malcolm Stent (Primary Contributor) |
 |
STENT Street Sign ~ Personalized Family Lastname Sign ~ Gameroom, Basement, Garage Sign Novelty** METAL ALUMINUM by The Lizton Sign Shop STENT Street Sign, A BRAND NEW SIGN!! Made of aluminum and high quality vinyl lettering and graphics this sign is 4 x 18 inches. Made to last for years outdoors the sign is nice enough to display indoors. Comes with two holes pre-punched for easy installation, corners are rounded. |
 |
Phage And the Origins of Molecular Biology, The Centennial Edition by John Cairns (Editor), Gunther S. Stent (Editor), James D. Watson (Editor) This hugely influential book, published in 1966 as a 60th birthday tribute to Max Delbrück, is now republished as The Centennial Edition. On first publication, the book was hailed as "[introducing] into the literature of science, for the first time, a self conscious historical element in which the participants in scientific discovery engage in writing their own chronicle. As such, it is an important document in the history of biology... "(Journal of History of Biology). And in another review it was described as "required reading for every student of experimental biology...[who] will sense the smell and rattle of the laboratory" (Bioscience). The book was a formative influence on many of today s leading scientists. Related Titles from the... |
| © 2009 BrightSurf.com |